SEC Form 4 · accession 0001209191-17-035995
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay T Flatley
Director
Period of report
May 24, 2017
Accepted (ET)
May 26, 2017 · 6:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 24, 2017 | P | 10,000 | $25.1517 | A | 11,500 | I | By the Flatley Family Trust |
| Common Stock | May 26, 2017 | P | 10,000 | $24.37 | A | 21,500 | I | By the Flatley Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $25.14 to $25.16. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.